# A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration

> **NCT01755494** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 64 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus(T2DM)

## Interventions

- **DRUG:** Saxagliptin 5 mg
- **DRUG:** Metformin XR 500 mg
- **DRUG:** Mertformin XR 2 x 500 mg
- **DRUG:** Komboglyze XR 5/500 mg
- **DRUG:** Komboglyze XR 5/1000 mg

## Key facts

- **NCT ID:** NCT01755494
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2013-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01755494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01755494, "A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01755494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*